Evidence map›Paper›PMID 41363051›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2026

Neoadjuvant Under-Dilated TIPS: Expanding Surgeries for Extrahepatic Malignancies in Patients With Cirrhosis and CSPH.

Dario Saltini, Davide Roccarina, Marco Senzolo, Cristian Caporali, Fabrizio Fanelli, Marcello Bianchini, Federico Casari, Angelica Ingravallo, Silvia Aspite, Tomas Guasconi and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neoadjuvant Under-Dilated TIPS: Expanding Surgeries for Extrahepatic Malignancies in Patients With Cirrhosis and CSPH.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Dario SaltiniSevere Liver Diseases (M.E.C.) Departmental Unit, Department of Medical Specialties, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, European Reference Network on Rare Liver Disorders (ERN Rare-Liver), Modena, Italy.
Davide RoccarinaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Marco SenzoloUnit of Vascular Liver Diseases and Treatment of Portal Hypertension, Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, University-Hospital of Padua, Padua, Italy.
Cristian CaporaliDivision of Interventional Radiology, University Hospital of Modena "Policlinico", Modena, Italy.
Fabrizio FanelliDepartment of Radiology, Interventional Radiology Unit, Careggi Hospital, Florence, Italy.
Marcello BianchiniSevere Liver Diseases (M.E.C.) Departmental Unit, Department of Medical Specialties, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, European Reference Network on Rare Liver Disorders (ERN Rare-Liver), Modena, Italy.
Federico CasariDivision of Interventional Radiology, University Hospital of Modena "Policlinico", Modena, Italy.
Angelica IngravalloDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Silvia AspiteDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Tomas GuasconiSevere Liver Diseases (M.E.C.) Departmental Unit, Department of Medical Specialties, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, European Reference Network on Rare Liver Disorders (ERN Rare-Liver), Modena, Italy.
Antonio PiscopoGastroenterology Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Andrea Salome Velasco MayorgaGastroenterology Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Barbara CatellaniHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Gian Piero GuerriniHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Stefano Di SandroHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Fabio StaderiniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Umberto CilloHepato-Pancreato-Biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
Fabrizio Di BenedettoHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Antonio ColecchiaGastroenterology Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, Modena, Italy.
Fabio MarraDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0001-8629-0878
Patrizia BurraUnit of Vascular Liver Diseases and Treatment of Portal Hypertension, Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, University-Hospital of Padua, Padua, Italy.ORCID 0000-0002-8791-191X
Francesco VizzuttiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Filippo SchepisSevere Liver Diseases (M.E.C.) Departmental Unit, Department of Medical Specialties, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, European Reference Network on Rare Liver Disorders (ERN Rare-Liver), Modena, Italy.ORCID 0000-0001-6549-5102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsPortal hypertension is a major challenge in patients with cirrhosis requiring surgery. This study aimed to evaluate the efficacy of under-dilated neoadjuvant transjugular intrahepatic portosystemic shunt (U.N-TIPS) in enabling elective extrahepatic oncologic surgery in patients with cirrhosis and clinically significant portal hypertension (CSPH).

methodsThis retrospective multicenter analysis included 34 patients who underwent U.N-TIPS (diameter 5-7 mm) between June 2018 and April 2023. The primary outcome was the ability of U.N-TIPS to enable surgical interventions otherwise contraindicated. Secondary outcomes were perioperative complications, overt hepatic encephalopathy (OHE), heart failure, and survival rates at 6 months and 1 year post-TIPS.

resultsAt baseline, 53% of patients had decompensated cirrhosis. The most common malignancies were colorectal (32%) and gastric (15%). Final diameters were 5/6/7 mm in 9/17/8 patients, respectively. Mean porto-caval pressure gradient (PCPG) significantly decreased from 21 ± 4.5 to 11 ± 3.2 mmHg (p < 0.001), with all patients achieving PCPG < 16 mmHg. Thirty-two patients (94%) underwent planned surgery, with a median TIPS-to-surgery interval of 42 days (IQR 45). Postoperative complications occurred in 38% of patients-mostly infections-and were independently associated with pre-surgery MELD score and haemoglobin. Post-TIPS OHE occurred in 22%, with no persistent cases; symptomatic heart failure developed in 6%. Six-month and one-year survival rates were 85% and 76%, respectively, without significant difference between pre-TIPS compensated and decompensated patients (p = 0.21).

conclusionsU.N-TIPS represents an applicable strategy for enabling curative oncologic surgery in selected patients with cirrhosis and CSPH. Under-dilation reduces shunt-related complications while preserving hemodynamic efficacy, expanding TIPS applicability. IMPACT AND IMPLICATIONS: U.N-TIPS addresses the critical barrier of portal hypertension in oncologic patients with cirrhosis, offering access to surgical treatments considered unfeasible while maintaining an adequate safety profile. These findings are particularly significant for hepatologists, oncologists, interventional radiologists, and surgeons managing the increasingly common clinical scenario of cirrhosis with concurrent extrahepatic malignancies. In clinical practice, our results support the implementation of multidisciplinary tumour boards that incorporate portal pressure assessment and TIPS indication in pre-surgical planning. However, large, controlled studies are needed to compare outcomes between compensated patients with CSPH who undergo U.N-TIPS versus those who do not receive this intervention.

Indexed as

Hypertension, PortalLiver CirrhosisPortasystemic Shunt, Transjugular IntrahepaticAgedFemaleHepatic EncephalopathyHumansMaleMiddle AgedNeoadjuvant TherapyPostoperative ComplicationsRetrospective StudiesTreatment Outcomeascitescirrhosishepatic encephalopathyoncologic surgeryportal hypertensionportosystemic shunt

Identifiers

PMID41363051
PMCPMC12687307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.